376 related articles for article (PubMed ID: 30670446)
21. In MDS, is higher risk higher reward?
Sanz GF
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):381-390. PubMed ID: 31808894
[TBL] [Abstract][Full Text] [Related]
22. Raising the bar for lower-risk myelodysplastic syndromes.
Venugopal S; Sekeres MA
Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589
[TBL] [Abstract][Full Text] [Related]
23. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
Montalban-Bravo G; Garcia-Manero G
Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
[TBL] [Abstract][Full Text] [Related]
24. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
Lucero J; Al-Harbi S; Yee KWL
Curr Oncol; 2023 Jun; 30(7):6177-6196. PubMed ID: 37504319
[TBL] [Abstract][Full Text] [Related]
25. How to treat MDS without stem cell transplantation.
Gattermann N
Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S30-6. PubMed ID: 19857591
[TBL] [Abstract][Full Text] [Related]
26. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
27. First-line Therapeutic Strategies for Myelodysplastic Syndromes.
Santini V
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S31-S36. PubMed ID: 28760300
[TBL] [Abstract][Full Text] [Related]
28. Therapy for lower-risk MDS.
Carraway HE; Saygin C
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):426-433. PubMed ID: 33275714
[TBL] [Abstract][Full Text] [Related]
29. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes.
Komrokji RS
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S39-43. PubMed ID: 27521322
[TBL] [Abstract][Full Text] [Related]
30. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
[TBL] [Abstract][Full Text] [Related]
31. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
32. Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.
Uy N; Singh A; Gore SD; Prebet T
Expert Opin Pharmacother; 2017 Aug; 18(12):1213-1224. PubMed ID: 28675065
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.
Kewan T; Stahl M; Bewersdorf JP; Zeidan AM
Curr Hematol Malig Rep; 2024 Jun; 19(3):138-150. PubMed ID: 38632155
[TBL] [Abstract][Full Text] [Related]
34. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2011 Jun; 86(6):490-8. PubMed ID: 21594886
[TBL] [Abstract][Full Text] [Related]
35. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes - Advances in treatment.
McCullough KB; Patnaik MM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101130. PubMed ID: 32460984
[TBL] [Abstract][Full Text] [Related]
36. Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?
Oran B
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S43-9. PubMed ID: 26297277
[TBL] [Abstract][Full Text] [Related]
37. Myelodysplastic syndromes: what do hospitalists need to know?
Zeidan AM; Faltas B; Douglas Smith B; Gore S
J Hosp Med; 2013 Jun; 8(6):351-7. PubMed ID: 23666619
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of higher risk myelodysplastic syndromes].
Usuki K
Rinsho Ketsueki; 2019; 60(9):1131-1139. PubMed ID: 31597836
[TBL] [Abstract][Full Text] [Related]
39. Existing agents, novel agents, or transplantation for high-risk MDS.
Scott BL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):411-417. PubMed ID: 33275695
[TBL] [Abstract][Full Text] [Related]
40. Improving Treatment for Myelodysplastic Syndromes Patients.
Montoro J; Yerlikaya A; Ali A; Raza A
Curr Treat Options Oncol; 2018 Oct; 19(12):66. PubMed ID: 30362079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
